Regeneron Pharmaceuticals And Sanofi Today Announced That National Medical Products Administration In China Has Approved Dupixent (Dupilumab) As An Add-on Maintenance Treatment For Adults With Uncontrolled Chronic Obstructive Pulmonary Disease
Portfolio Pulse from Nabaparna Bhattacharya
Regeneron Pharmaceuticals and Sanofi have received approval from China's National Medical Products Administration for Dupixent as an add-on treatment for adults with uncontrolled COPD. This follows EU approval and is based on successful Phase 3 trials.
September 27, 2024 | 11:05 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Regeneron Pharmaceuticals' Dupixent has been approved in China for COPD treatment, potentially boosting its market presence and revenue in a key region.
The approval of Dupixent in China for COPD treatment is significant due to the high prevalence of the disease and its alignment with China's public health priorities. This could lead to increased sales and market penetration for Regeneron.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Sanofi's Dupixent has been approved in China for COPD treatment, which could enhance its market share and revenue in a major market.
Sanofi's Dupixent approval in China for COPD is crucial given the disease's prevalence and the government's health initiatives. This approval could lead to increased sales and market expansion for Sanofi.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80